Fondaparinux Sodium

Fondaparinux Sodium is a synthetic anticoagulant that selectively inhibits Factor Xa, a key enzyme in the coagulation cascade. It is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE).

Indications

-Prevention of deep vein thrombosis (DVT) in patients undergoing surgery, such as hip fracture, hip replacement, knee replacement, or abdominal surgery. -Treatment of acute deep vein thrombosis (DVT) when administered in conjunction with warfarin. -Treatment of acute pulmonary embolism (PE) when administered in conjunction with warfarin.

Dosage

-Prevention of DVT: 2.5 mg once daily, starting 6-8 hours after surgery. -Treatment of DVT and PE: 5 mg (body weight < 50 kg), 7.5 mg (body weight 50-100 kg), or 10 mg (body weight > 100 kg) once daily.

Contra-Indications

-Severe renal impairment (creatinine clearance < 30 mL/min). -Active major bleeding. -Bacterial endocarditis. -Hypersensitivity to Fondaparinux Sodium or any component of the formulation.

Special Precautions

-Use with caution in patients with moderate renal impairment. -Monitor for signs of bleeding, especially in patients with risk factors such as recent surgery, trauma, or concomitant use of other anticoagulants. -Consider risk of spinal/epidural hematoma in patients undergoing neuraxial anesthesia or spinal puncture.

Side Effects

-Bleeding complications (e.g., hematoma, hemorrhage). -Anemia. -Thrombocytopenia. -Injection site reactions (e.g., pain, bruising). -Nausea.

Drug Interactions

-Increased risk of bleeding when used with other anticoagulants, antiplatelet agents, or NSAIDs. -Potential interaction with drugs affecting renal function.